比较 Personalis（纳斯达克股票代码：PSNL）和 MedTech 收购（纳斯达克股票代码：MTAC）

MedTech Acquisition (NASDAQ:MTAC – Get Rating) and Personalis (NASDAQ:PSNL – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MedTech Acquisition and Personalis, as provided by MarketBeat.com.

Personalis has a consensus price target of $8.00, indicating a potential upside of 161.44%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than MedTech Acquisition.

Volatility & Risk

MedTech Acquisition has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, Personalis has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Valuation & Earnings

This table compares MedTech Acquisition and Personalis' gross revenue, earnings per share (EPS) and valuation.

MedTech Acquisition has higher earnings, but lower revenue than Personalis.

Profitability

This table compares MedTech Acquisition and Personalis' net margins, return on equity and return on assets.

Insider & Institutional Ownership

74.9% of MedTech Acquisition shares are held by institutional investors. Comparatively, 60.8% of Personalis shares are held by institutional investors. 20.0% of MedTech Acquisition shares are held by company insiders. Comparatively, 7.5% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MedTech Acquisition beats Personalis on 6 of the 10 factors compared between the two stocks.

About MedTech Acquisition

(Get Rating)

MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States.. The company was incorporated in 2020 and is based in Greenwich, Connecticut.

About Personalis

(Get Rating)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Receive News & Ratings for MedTech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedTech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.